NAFLD

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Omeprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 19/February/2017, 11.59 pm

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Omeprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 19/February/2017, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Lansoprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 10/February/2017, 11.59 pm

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Lansoprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 10/February/2017, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Triiodothyronine, a thyroid hormone (T3),  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 30/January/2017, 11.41 pm

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Triiodothyronine, a thyroid hormone (T3),  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 30/January/2017, 11.41 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Lycopene, isolated from Gac, Guava and Tomato,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 26/December/2017, 11.37 pm

Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Lycopene, isolated from Gac, Guava and Tomato,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 26/December/2017, 11.37 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Rosmarinic acid, isolated from Rosemary officinalis, and Perilla frutescens,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 24/December/2017, 11.51 pm

Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Rosmarinic acid, isolated from Rosemary officinalis, and Perilla frutescens,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 24/December/2017, 11.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Trimetazidine (TMZ)[brand names: 3 Kat, Adexor, Aiyiling, Angimax, Angimet, Anginox, Angintriz, Angiozil, Angirel etc., ], used in the treatment of angina pectoris,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 11/December/2017, 10.58 pm

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Trimetazidine (TMZ)[brand names: 3 Kat, Adexor, Aiyiling, Angimax, Angimet, Anginox, Angintriz, Angiozil, Angirel etc., ], used in the treatment of angina pectoris,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 11/December/2017, 10.58 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while only 6-25% of Asian populations suffer from it; (2) 75 to 100 million…

read more